CE vs SSRM

Celanese Corporation exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health. Despite a recent 1-year price recovery, the company is struggling with negative profit margins (-12.21%), a deeply negative ROE (-22.52%), and a high Debt/Equity ratio of 2.89. Revenue and earnings are in sharp decline, with YoY EPS growth collapsing by 88.3%. The disconnect between the bearish deterministic health scores and the 'Buy' analyst consensus suggests a speculative outlook rather than a fundamental one.

With a Piotroski F-Score of 4/9, SSRM exhibits stable financial health, though the absence of an Altman Z-Score leaves a gap in bankruptcy risk quantification. The stock is currently priced at $31.75, trading at a premium to its Graham Number ($26.82) but significantly below its growth-based Intrinsic Value ($54.58). While the company shows explosive YoY earnings growth and a very low forward P/E of 6.13, the 'Çöpler Incident' noted in the 10-K represents a critical qualitative risk. Despite a bearish technical trend score, the fundamental valuation and analyst consensus suggest strong upside potential.